The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Liraglutide Market From 2026 To 2030?
The market size for liraglutide has experienced substantial growth over recent years. It is anticipated to expand from $6.88 billion in 2025 to $7.45 billion in 2026, at a compound annual growth rate (CAGR) of 8.2%. This historical growth can be attributed to several factors including the rising global prevalence of type 2 diabetes, the clinical success observed with glp-1 receptor agonists, the demand for therapies that address both glucose control and weight, the approval of liraglutide for diabetes and obesity indications, and increasing physician confidence in injectable incretin therapies.
The liraglutide market is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $10.23 billion, exhibiting a compound annual growth rate (CAGR) of 8.3%. This anticipated growth during the forecast period is driven by factors such as the escalating worldwide obesity crisis, a rising inclination towards diabetes therapies that prioritize weight management, the expansion of screening initiatives for metabolic disorders, an increasing patient need for potent appetite-reducing treatments, and ongoing advancements coupled with enhanced understanding of GLP-1 based treatments. Key trends characterizing this period encompass the widespread integration of liraglutide in Type 2 diabetes management, its increasing application in medical weight management, broader acceptance of injectable GLP-1 therapies, the development of extended metabolic disease management programs, and a heightened emphasis on the combined advantages of blood sugar regulation and weight reduction.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18659&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Liraglutide Market?
The expanding diabetic population is projected to drive the future growth of the liraglutide market. Diabetes is a persistent ailment characterized by the body’s inability to adequately control blood sugar, stemming from either inadequate insulin generation or inefficient insulin utilization. The occurrence of diabetes is on the rise, influenced by factors globally like inactive routines, poor eating habits, and growing levels of obesity. Medications for diabetes, including liraglutide, function by imitating the GLP-1 hormone, which in turn boosts insulin release, reduces blood sugar, and facilitates weight reduction, thus assisting in the treatment of type 2 diabetes. As an illustration, a March 2024 report from the Government of the United Kingdom, a UK-based information source, indicated that in March 2023, the percentage of individuals with type 1 diabetes in England receiving all 8 care processes at NDA-participating GP practices rose to 43.8%, up from 35.2% in the preceding year. Consequently, the growing number of individuals with diabetes is fueling the expansion of the liraglutide market.
Which Segments Are Included In The Analysis Of The Liraglutide Market?
The liraglutide market covered in this report is segmented –
1) By Brands: Victoza, Saxenda
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies And Drug Stores, Online Pharmacies
3) By Type Of Application: Diabetes Treatment, Weight Management
4) By End-Users: Hospitals And Clinics, Homecare Settings
Subsegments:
1) By Victoza: Type 2 Diabetes Treatment Or Weight Management
2) By Saxenda: Weight Loss Treatment Or Obesity Management
Which Trends Are Impacting The Growth Of The Liraglutide Market?
Leading companies in the liraglutide market are developing new products, such as generic GLP-1, with the goal of expanding treatment alternatives and meeting the market’s demand for more affordable options. Generic GLP-1 refers to versions of GLP-1 receptor agonists manufactured after the patent protection on the original branded medications has expired, providing cost-effective solutions for managing conditions like type 2 diabetes and obesity. For instance, in June 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, introduced the first generic GLP-1, similar to Victoza, into the U.S. market, thereby fulfilling the growing requirement for these treatments. Liraglutide injections are prescribed to improve blood sugar control in adults and children aged 10 and above with type 2 diabetes, and also to decrease the risk of cardiovascular incidents in adults who have type 2 diabetes and pre-existing cardiovascular conditions.
Which Key Industry Participants Are Active In The Liraglutide Market?
Major companies operating in the liraglutide market are Novo Nordisk A/S
Read the full liraglutide market report here:
https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report
What Are The Leading Geographic Regions In The Liraglutide Market?
North America was the largest region in the liraglutide market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Liraglutide Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=18659&type=smp
Browse Through More Reports Similar to the Global Liraglutide Market 2026, By The Business Research Company
Liraglutide Market Report 2026
https://www.thebusinessresearchcompany.com/report/liraglutide-global-market-report
Liraglutide And Semaglutide Market Report 2026
https://www.thebusinessresearchcompany.com/report/liraglutide-and-semaglutide-global-market-report
Lisinopril Market Report 2026
https://www.thebusinessresearchcompany.com/report/lisinopril-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model